BioCryst Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . BioCryst Pharmaceuticals
BCRX Stock  USD 7.60  0.11  1.47%   
BioCryst Pharmaceuticals financial statements provide useful quarterly and yearly information to potential BioCryst Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioCryst Pharmaceuticals financial statements helps investors assess BioCryst Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioCryst Pharmaceuticals' valuation are summarized below:
Gross Profit
10.9 M
Profit Margin
(0.30)
Market Capitalization
1.6 B
Enterprise Value Revenue
4.9768
Revenue
412.6 M
We have found one hundred twenty available fundamental signals for BioCryst Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioCryst Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 124 M in 2024. Enterprise Value is likely to rise to about 115.2 M in 2024

BioCryst Pharmaceuticals Total Revenue

347.98 Million

Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 113.7 M or Selling General Administrative of 209.5 M, as well as many indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

BioCryst Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets542.8 M517 M239 M
Slightly volatile
Short and Long Term Debt Total891.1 M848.7 M242.2 M
Slightly volatile
Total Current Liabilities157.5 M150 M72.1 M
Slightly volatile
Property Plant And Equipment Net22 M21 M8 M
Slightly volatile
Accounts Payable21.9 M20.9 M10.6 M
Slightly volatile
Cash65.7 M110.6 M107.7 M
Slightly volatile
Non Current Assets Total24.6 M21 M25.3 M
Pretty Stable
Cash And Short Term Investments410.3 M390.8 M191.7 M
Slightly volatile
Common Stock Shares Outstanding201.8 M192.2 M106.6 M
Slightly volatile
Non Current Liabilities Total863.6 M822.5 M236.7 M
Slightly volatile
Other Current Assets22.4 M21.3 M11.1 M
Very volatile
Total Liabilities1 B972.5 M308 M
Slightly volatile
Property Plant And Equipment Gross20.1 M19.1 M8.3 M
Slightly volatile
Total Current Assets520.8 M496 M213.9 M
Slightly volatile
Short Term Debt2.5 M2.6 M21.9 M
Slightly volatile
Common Stock Total Equity2.2 M2.1 M1.2 M
Slightly volatile
Short Term Investments292.3 M278.3 M68.7 M
Slightly volatile
Common Stock2.2 M2.1 M1.2 M
Slightly volatile
Other Liabilities46.2 K48.6 K3.6 M
Slightly volatile
Current Deferred Revenue1 M1.1 M190.2 M
Slightly volatile
Property Plant Equipment18.6 M17.7 M8.1 M
Slightly volatile
Other Assets664.1 M632.5 M244.4 M
Slightly volatile
Net Receivables59.8 M57 M20.3 M
Slightly volatile
Long Term Debt Total164.3 M156.5 M63.5 M
Slightly volatile
Capital Surpluse745.7 M1.3 B720.8 M
Slightly volatile
Deferred Long Term Liabilities46.2 K48.6 K2.9 M
Slightly volatile
Short and Long Term Debt35.1 M34.5 M31.5 M
Slightly volatile
Capital Lease Obligations23 M13.9 M13.8 M
Slightly volatile
Net Invested Capital297 M355.7 M209.1 M
Slightly volatile
Net Working Capital252.2 M346 M147.4 M
Slightly volatile
Capital Stock1.9 M2.1 M1.4 M
Slightly volatile

BioCryst Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1 M1.7 M819.8 K
Slightly volatile
Selling General Administrative209.5 M199.5 M57.8 M
Slightly volatile
Total Revenue348 M331.4 M91.5 M
Slightly volatile
Other Operating Expenses456.9 M435.1 M172.6 M
Slightly volatile
Cost Of Revenue9.2 M4.7 M7.6 M
Pretty Stable
Total Operating Expenses452.2 M430.6 M169.9 M
Slightly volatile
Income Tax Expense325.5 K310 K4.8 M
Very volatile
Research Development227.4 M216.6 M109 M
Slightly volatile
Selling And Marketing Expenses7.6 M14.4 M7.2 M
Slightly volatile
Interest Income14.7 M14 M4.7 M
Slightly volatile
Reconciled Depreciation1.1 M1.6 M852.2 K
Slightly volatile

BioCryst Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow321.6 M306.2 M119.2 M
Slightly volatile
Depreciation970.6 K1.7 M736.2 K
Slightly volatile
Other Non Cash Items111.9 M106.5 M25.5 M
Slightly volatile
Capital Expenditures2.1 M2.2 M1.4 M
Pretty Stable
Total Cash From Financing Activities57.9 M32.5 M91 M
Slightly volatile
End Period Cash Flow66.1 M112.4 M108.5 M
Slightly volatile
Stock Based Compensation52.8 M55.6 M25.9 M
Pretty Stable
Net Borrowings64.6 M84 M51.3 M
Slightly volatile
Issuance Of Capital Stock324.9 K342 K45.5 M
Slightly volatile
Exchange Rate Changes56.8 K63.9 K69.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.33.473822.3743
Pretty Stable
Days Sales Outstanding59.5962.72184.9 K
Slightly volatile
Average Payables12.4 M11.8 M12.2 M
Slightly volatile
Stock Based Compensation To Revenue0.160.16782.4209
Slightly volatile
Capex To Depreciation1.241.313.3099
Very volatile
EV To Sales5.425.700922.2385
Pretty Stable
Payables Turnover0.210.22311.3001
Slightly volatile
Sales General And Administrative To Revenue0.570.60191.0964
Very volatile
Research And Ddevelopement To Revenue0.620.65352.9967
Slightly volatile
Capex To Revenue0.00620.00650.0663
Slightly volatile
Cash Per Share2.132.02391.3255
Slightly volatile
Days Payables Outstanding1.6 K1.6 K4.4 K
Slightly volatile
Income Quality0.40.420.7222
Slightly volatile
Intangibles To Total Assets0.00330.00380.0041
Slightly volatile
Current Ratio3.143.30673.5346
Pretty Stable
Receivables Turnover2.985.81944.0943
Pretty Stable
Graham Number6.317.928110.2581
Slightly volatile
Capex Per Share0.01070.01130.0175
Pretty Stable
Average Receivables18.8 M28.8 M29.9 M
Very volatile
Revenue Per Share1.811.72430.6335
Slightly volatile
Interest Debt Per Share5.024.78411.7166
Slightly volatile
Debt To Assets1.651.56930.6732
Slightly volatile
Days Of Payables Outstanding1.6 K1.6 K4.4 K
Slightly volatile
Ebt Per Ebit2.072.18141.2466
Slightly volatile
Quick Ratio2.963.11553.5163
Slightly volatile
Net Income Per E B T1.051.00141.0731
Slightly volatile
Cash Ratio0.70.73771.5448
Very volatile
Days Of Sales Outstanding59.5962.72184.9 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.071.02281.0465
Very volatile
Fixed Asset Turnover9.4915.78618.1819
Slightly volatile
Debt Ratio1.651.56930.6732
Slightly volatile
Price Sales Ratio3.33.473822.3743
Pretty Stable
Asset Turnover0.670.64110.3047
Slightly volatile

BioCryst Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap124 M100.4 M106.2 M
Slightly volatile
Enterprise Value115.2 M112.6 M117.2 M
Slightly volatile

BioCryst Fundamental Market Drivers

Cash And Short Term Investments390.8 M

BioCryst Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioCryst Pharmaceuticals Financial Statements

BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1 M
Total Revenue331.4 M348 M
Cost Of Revenue4.7 M9.2 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 0.60  0.57 
Research And Ddevelopement To Revenue 0.65  0.62 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.72  1.81 
Ebit Per Revenue(0.31)(0.33)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY